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Dual Supramolecular Nanoparticle Vectors Enable
CRISPR/Cas9-Mediated Knockin of Retinoschisin
1 Gene—A Potential Nonviral Therapeutic Solution
for X-Linked Juvenile Retinoschisis
Shih-Jie Chou, Peng Yang, Qian Ban, Yi-Ping Yang, Mong-Lien Wang, Chian-Shiu Chien,
Shih-Jen Chen, Na Sun, Yazhen Zhu, Hongtao Liu, Wenqiao Hui, Tai-Chi Lin, Fang Wang,
Ryan Yue Zhang, Viet Q. Nguyen, Wenfei Liu, Mengxiang Chen, Steve J. Jonas,
Paul S. Weiss,* Hsian-Rong Tseng,* and Shih-Hwa Chiou*
The homology-independent targeted integration (HITI) strategy enables effective CRISPR/Cas9-mediated knockin of ther-
apeutic genes in nondividing cells in vivo, promising general therapeutic solutions for treating genetic diseases like X-
linked juvenile retinoschisis. Herein, supramolecular nanoparticle (SMNP) vectors are used for codelivery of two DNA
plasmids—CRISPR-Cas9 genome-editing system and a therapeutic gene, Retinoschisin 1 (RS1)—enabling clustered reg-
ularly interspaced short palindromic repeats (CRISPR)-associated protein 9 (CRISPR/Cas9) knockin of the RS1 gene with
HITI. Through small-scale combinatorial screenings, two SMNP vectors, with Cas9 and single guide RNA (sgRNA)-
plasmid in one and Donor-RS1 and green fluorescent protein (GFP)-plasmid in the other, with optimal delivery perfor-
mances are identified. These SMNP vectors are then employed for CRISPR/Cas9 knockin of RS1/GFP genes into the
mouse Rosa26 safe-harbor site in vitro and in vivo. The in vivo study involves intravitreally injecting the two SMNP vec-
tors into the mouse eyes, followed by repeated ocular imaging by fundus camera and optical coherence tomography, and
pathological and molecular analyses of the harvested retina tissues. Mice ocular organs retain their anatomical integrity,
a single-copy 3.0-kb RS1/GFP gene is precisely integrated into the Rosa26 site in the retinas, and the integrated RS1/GFP
gene is expressed in the retinas, demonstrating CRISPR/Cas9 knockin of RS1/GFP gene.
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The clustered regularly interspaced short palindromic repeats,
CRISPR-associated protein 9 (CRISPR/Cas9) system is revolu-
tionizing gene therapy.[1] A CRISPR/Cas9-mediated gene editing
system is composed of two functional components, i.e., Cas9 en-
donuclease and an engineered short, single-guide RNA (sgRNA),
which form a ribonucleoprotein complex, Cas9•sgRNA. Based
on a base-pairing mechanism, Cas9•sgRNA complex recognizes
and cuts the targeted site, precisely inducing a double-strand
break (DSB).[1] Subsequently, endogenous DNA repair occurs
via either a nonhomologous end joining (NHEJ) or a homology
directed repair (HDR) pathway. As a general therapeutic solu-
tion for treating genetic diseases,[2] the HDR pathway is often
adopted for CRISPR/Cas9-mediated knockin,[3] by which a ther-
apeutic gene carried by donor DNA (dDNA) is integrated into
DSB. However, HDR-based CRISPR/Cas9-mediated knockin is
less efficient in vivo since the HDR pathway is not readily acces-
sible to nondividing cells in tissue.[4] By contrast, the NHEJ path-
way is active in both nondividing and proliferating cells, and thus,
can be adopted to achieve more efficient in vivo CRISPR/Cas9-
mediated knockin. A homology-independent targeted integration
(HITI) strategy[5] was developed based on the NHEJ pathway to
enable robust knockin of nondividing cells in vivo. In brief, HITI
strategy introduces two predetermined CRISPR/Cas9 target sites
into dDNA. After cutting the targeted sites present in both ge-
nomic DNA and dDNA, the resulting three DSB sites under-
goes endogenous DNA repair via the NHEJ pathway to achieve
gene integration.[5] In animal studies, the HITI strategy enables
more efficient CRISPR/Cas9-mediated knockin, suitable for a lo-
cal gene-editing solution in organs, like eyes and brains.[5a] How-
ever, the technical challenge remains to develop safe and reliable
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delivery vectors that can codeliver Cas9•sgRNA and dDNA into
the target cells and/or tissues.
X-linked juvenile retinoschisis, XLRS is a condition character-
ized by impaired vision that begins in childhood in males. Ap-
proximately 200 mutations of the RS1 gene have been identi-
fied as associated with either decreases in or complete loss of
functional retinoschisin, which disrupts themaintenance and or-
ganization of cells in the retina.[6] Recently, a small number of
clinical trials[7] were initiated to evaluate the safety and efficacy
of adeno-associated virus (AAV)-based gene therapy approaches,
which introduce functional retinoschisin in retina to treat XLRS.
To date, none of the AAV-based RS1 gene therapy approaches[8]
has reached a satisfactory clinical endpoint. Meanwhile, re-
searchers have been exploring CRISPR/Cas9-mediated knockin
of RS1 gene to achieve a curative therapeutic solution for XLRS.
While AAV[9] is also frequently used for delivering CRISPR/Cas9
system, its limited packaging capacity (<4.7 kb)[10] and safety
concerns on viral integration and immunogenicity remain. Al-
ternative approaches harness the potential of nonviral vectors,[11]
including lipids,[12] polymers,[13] and nanoparticles[14] for carry-
ing Cas9, guide RNA (gRNA), and donor DNA (dDNA). Although
there has been substantial progress made for CRISPR/Cas9-
mediated gene knockout,[14c,15] and knockdown[16] using nonviral
vectors along the NHEJ pathway, relatively limited results have
been obtained for CRISPR/Cas9-mediated knockin,[14d,17] espe-
cially for integration of a full-length gene. We envision exploit-
ing the combined use of nonviral vectors with the more effective
HITI strategy to facilitate CRISPR/Cas9-mediated knockin of a
full-length therapeutic gene as a more effective and general non-
viral therapeutic solution for many genetic diseases.
Previously, we demonstrated a convenient and flexible
self-assembled synthetic strategy for producing supramolecu-
lar nanoparticle[18] (SMNP) vectors by mixing three molecu-
lar building blocks, i.e., 𝛽-cyclodextrin (CD)-grafted branched
polyethyleneimine (CD-PEI), adamantane (Ad)-grafted polyami-
doamine dendrimer (Ad-PAMAM), and Ad-grafted poly(ethylene
glycol) (Ad-PEG). The multivalent Ad/CD molecular recognition
allowsmodular control over the sizes, surface chemistry, and pay-
loads of SMNP vectors, promising a diversity of imaging[18,19]
and therapeutic applications.[20] We have shown that this self-
assembly strategy can be utilized for combinatorial formulation
and screening of SMNPs to optimize formulations with signifi-
cantly improved delivery performance.[21]
Our past experience[22] in utilizing SMNP vectors for deliv-
ery of DNA plasmid prompted us to exploit the combined use of
SMNP vectors with the HITI strategy for in vivo CRISPR/Cas9-
mediated knockin of RS1 gene (Scheme 1a) as a potential non-
viral therapeutic solution for XLRS. By conducting small-scale
combinatorial formulations and screenings,[21] two SMNP vec-
tors, i.e., Cas9/sgRNA-plasmid⊂SMNPs and Donor-RS1/GFP-
plasmid⊂SMNPs with optimal delivery performance were iden-
tified. We envision that, by performing intravitreal injection
of the two SMNP vectors in a mouse model, Cas9/sgRNA-
plasmid (9.3 kb, detailed gene map see Figure S1 in the
Supporting Information) and Donor-RS1/GFP-plasmid (4.9 kb,
detailed gene map see Figure S1 in the Supporting Informa-
tion) can be introduced into the retina, initiating CRISPR/Cas9-
mediated knockin of RS1/GFP gene in two consecutive steps. In
Step 1, Cas9•sgRNA specifically recognizes and cuts a sgRNA
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Scheme 1. a) Schematic illustration showing that two supramolecular nanoparticle (SMNP) vectors were developed for codelivery of Cas9/sgRNA-
plasmid and Donor-RS1/GFP-plasmid, enabling CRISPR/Cas9-mediated knockin of RS1 gene in mouse retinas. After Cas9•sgRNA formation in vivo,
CRISPR/Cas9-mediated knockin of RS1 gene is carried out in two consecutive steps following the homology-independent targeted integration (HITI)
strategy. b) A self-assembled synthetic strategy adopted for preparation of Cas9/sgRNA-plasmid⊂SMNPs through stoichiometric mixing of Cas9/sgRNA-
plasmid and four SMNP molecular building blocks, i.e., CD-PEI, Ad-PAMAM, Ad-PEG, and Ad-PEG-TAT. c) A self-assembly strategy adopted for prepa-
ration of Donor-RS1/GFP-plasmid⊂SMNPs.
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(sgRNA-Rosa26)-targeted sequence in a mouse Rosa26 safe-
harbor site [23] and two flanked sites adjacent to RS1/GFP genes
(within the Donor-RS1/GFP-plasmid), resulting in the formation
of three DSBs. In Step 2, DNA repair via the NHEJ pathway leads
to site-specific integration of RS1/GFP genes. To prepare for the
in vitro study, the B16mousemelanoma cell line (noRS1 gene ex-
pression) was employed as a model system for optimization. Our
self-assembly strategy[18] enables precise control over two syn-
thetic variables—(i) Ad-PAMAM/CD-PEI ratios, and (ii) the cov-
erage of amembrane penetration ligand, TAT.[20c] Through small-
scale combinatorial screenings, optimal performances were
identified for the formulations of Cas9/sgRNA-plasmid⊂SMNPs
and Donor-RS1/GFP-plasmid⊂SMNPs according to their per-
formances for inducing CRISPR/Cas9-mediated insertion and
deletion events (indels) and GFP transfection, respectively. The
two optimized SMNP vectors were then employed to achieve
CRISPR/Cas9-mediated knockin of RS1/GFP gene in growth-
synchronized B16 cells. The resulting RS1/GFP-knockin B16
cells were further characterized by fluorescencemicroscopy, poly-
merase chain reaction (PCR) assay, Sanger sequencing, and
quantitative PCR assay to confirm the successful integration of
3.0-kb RS1/GFP gene. Finally, we explored the feasibility of per-
forming CRISPR/Cas9-mediated knockin of RS1/GFP gene in
mouse retina by intravitreally coinjecting the two SMNP into
mice eyes. Ocular imaging with a fundus camera and optical co-
herence tomography (OCT), as well as pathological and molec-
ular analyses of the harvested retina tissues, were employed to
test the success and efficiency CRISPR/Cas9-mediated knockin
of RS1/GFP gene in mouse retinas.
Based on the self-assembly strategy, we first adopted a
small-scale combinatorial screening approach[21] in search of
a Cas9/sgRNA-plasmid⊂SMNPs formulation that optimized
performance for CRISPR/Cas9-mediated disruption at the
Rosa26 site (Figure 1a). After cell uptake of Cas9/sgRNA-
plasmid⊂SMNPs, Cas9•sgRNA was produced in cytoplasm, pre-
cisely introducing DSB at the Rosa26 site. The subsequent DNA
repair via the NHEJ pathway led to the indels. For optimization,
18 formulations of Cas9/sgRNA-plasmid⊂SMNPswere prepared
by systemically varying: (i) Ad-PAMAM/CD-PEI weight ratios =
0.5 to 3.0, and (ii) TAT ligand coverage = 1–10%, while keep-
ing the concentrations of Cas9/sgRNA-plasmid, Ad-PEG, and
CD-PEI at 0.01, 0.23, and 0.1 µg µL−1, respectively. Each for-
mulation of Cas9/sgRNA-plasmid⊂SMNPs (containing 1.0 µg
of Cas9/sgRNA-plasmid) was introduced to a well (in a 12-well
plate), where 1 × 105 B16 cells were starved in serum-free Dul-
becco’s modified Eagle’s medium (DMEM) overnight to syn-
chronize the cell cycles to G0/G1 phases.[24] 48 h after SMNPs
treatment, the B16 cells were subjected for genomic DNA ex-
traction, and the sgRNA-targeted surrounding region was am-
plified by PCR. T7 endonuclease I (T7E1) assay[3b] (Figure 1b)
was performed to quantify the indel frequency. T7 endonucle-
ase specifically recognizes and cleaves mismatched DNA am-
plicons associated with the indels. Along with the wild-type
(WT) amplicon (574 bp), two characteristic fragments (330 and
244 bp) were detected and quantified by electrophoretogram
(Figure 1c), reflecting the CRISPR/Cas9-mediated disruption
performances of the 18 formulations. The optimal performance
was identified for a Cas9/sgRNA-plasmid⊂SMNP formulation,
where Ad-PAMAM/CD-PEI is 1.5, and TAT coverage is 6%.
Replicated CRISPR/Cas9-mediated disruption tests were per-
formed to ensure the reproducibility of this optimal formula-
tion before knockin study (Figure S2, Supporting Information).
The control study, i.e., B16 cells treated by Cas9/sgRNA-
plasmid-encapsulated Lipofectamine 3000 agent (Cas9/sgRNA-
plasmid⊂LF3K) was conducted in parallel. T7E1 assay revealed
that themean indel frequencies were 23.7% for the Cas9/sgRNA-
plasmid⊂SMNPs and 15.8% for Cas9/sgRNA-plasmid⊂LF3K
(Figure S2, Supporting Information). In addition, to deter-
mine potential off-target effects of Cas9/sgRNA-plasmid, we per-
formed PCR and Sanger sequence at five of the top-ranking
predicted off-target sites of the sgRNA-Rosa26. The sequencing
results showed no datable off-target events in the top five pre-
dicted off-target sites (Figure S3, Supporting Information).
Based on a similar combinatorial screening approach,[21] we
next searched for a Donor-RS1/GFP-plasmid⊂SMNPs formula-
tion that optimizes GFP-transfection performance (Figure 2a).
Eighteen formulations of Donor-RS1/GFP-plasmid⊂SMNPs
were prepared by systemically varying (i) Ad-PAMAM/CD-PEI
weight ratios = 0.5–3.0, (ii) TAT ligand coverage = 1–10%,
while keeping the concentrations of Donor-RS1/GFP-plasmid,
Ad-PEG, and CD-PEI at 0.01, 0.23, and 0.1 µg µL−1, respec-
tively. After settling growth-synchronized B16 cells in culture
plates, each formulation of the SMNPs (containing 1.0 µg of
Donor-RS1/GFP-plasmid) was added to the cells. 48 h post
SMNP treatment, fluorescence microscopy was used to quan-
tify the GFP expression levels for individual formulations
(Figure 2b, enlarged fluorescence microscopy images see
Figure S4 in the Supporting Information). The quantitative anal-
ysis summarized in Figure 2c, revealed that the optimal GFP-
transfection performance was identified for a Donor-RS1/GFP-
plasmid⊂SMNPs formulation, where Ad-PAMAM/CD-PEI is
2.0, and TAT coverage is 6%. We further replicated the GFP-
transfection studies of the Donor-RS1/GFP-plasmid⊂SMNPs
with optimal formulation for three times (Figure S5, Sup-
porting Information). The control study, i.e., B16 cells treated
by Donor-RS1/GFP-plasmid-encapsulated Lipofectamine 3000
agent (Donor-RS1/GFP-plasmid⊂LF3K), was conducted in par-
allel. The flow-cytometry analysis showed the mean transfection
efficiencies were 82.9% for Donor-RS1/GFP-plasmid⊂SMNPs
and 82.5% for Donor-RS1/GFP-plasmid⊂LF3K (Figure S5, Sup-
porting Information). Viability of B16 cells after treatment with
different SMNP vectors and LF3K vectors was measured via cell
counting kit-8 (CCK-8) assay. The experimental data (Figure S6,
Supporting Information) showed B16 cells kept high viability af-
ter treatment of SMNP vectors for 24 and 48 h, while LF3K vec-
tors exhibited a remarkable cytotoxicity against B16 cells.
The studies above prompted us to explore the feasibility of co-
encapsulating both Cas9/sgRNA-plasmid and Donor-RS1/GFP-
plasmid into a single SMNP vector in order to simplify the
complicated procedures using the two vectors. Based on the
previous formulation conditions, we prepared Cas9/sgRNA-
plasmid+Donor-RS1/GFP-plasmid⊂SMNPs via stoichiometric
mixing of the two DNA plasmids with the SMNP building
blocks. The resulting Cas9/sgRNA-plasmid+Donor-RS1/GFP-
plasmid⊂SMNPs were subjected to both CRISPR/Cas9-
mediated disruption and GFP-transfection studies. The results
(Figure S7, Supporting Information) suggested that such coen-
capsulated SMNP vector exhibited significantly compromised
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Figure 1. a) Schematic illustration of CRISPR/Cas9-mediated disruption at the Rosa26 site in B16 cells treated by Cas9/sgRNA-plasmid⊂SMNPs. After
cell uptake of SMNPs, Cas9•sgRNA was produced to introduce DSB precisely at the Rosa26 site. Subsequent DNA repair via the NHEJ pathway led to
insertion and deletion events (indels). b) T7 endonuclease I (T7E1) assay was employed to quantify the indel frequency, reflecting the CRISPR/Cas9-
mediated disruption performance. c) Electrophoretograms were used to quantify the two characteristic fragments (330 and 244 bp) associated with the
indels along with the wild-type amplicon (574 bp). An optimal formulation of Cas9/sgRNA-plasmid⊂SMNPs was identified (*).
performance in both CRISPR/Cas9-mediated disruption (5.1%)
and GFP transfection (20%).
Scanning electron microscopy (SEM), transmission elec-
tron microscopy (TEM), and dynamic light scattering (DLS)
analyses were used to characterize the optimized Cas9/sgRNA-
plasmid⊂SMNPs, Donor-RS1/GFP-plasmid⊂SMNPs, and
Cas9/sgRNA-plasmid+Donor-RS1/GFP-plasmid⊂SMNPs. The
SEM and TEM images and size distributions are shown in
Figure 3a,b, and suggest that these two optimized formula-
tions conferred homogeneous spherical morphologies with
narrow size distributions to these two SMNP vectors. The
coencapsulated SMNPs have larger sizes and size distributions
(Figure 3a,b), which might be responsible for their reduced
performance. We note that the sizes observed by SEM and TEM
are smaller than the hydrodynamic size (Figure S8, Supporting
Information), measured by DLS, due to dehydration of SMNPs
during sample preparation for electron microscopy. According
to stoichiometric calculations (see the Supporting Informa-
tion), we estimate that ≈1–2 copies of Cas9/sgRNA-plasmid
and 2–3 copies of Donor-RS1/GFP-plasmid were encapsulated
into each Cas9/sgRNA-plasmid⊂SMNP and Donor-RS1/GFP-
plasmid⊂SMNP under the optimized formulation conditions,
respectively.
Using the two optimal SMNPs formulations, growth-
synchronized B16 cells were treated by both Cas9/sgRNA-
plasmid⊂SMNPs and Donor-RS1/GFP-plasmid⊂SMNPs (each
containing 1.0 µg of plasmid) for CRISPR-Cas9-mediated
knockin of RS1/GFP gene into the Rosa26 site via the HITI
pathway (Figure 4a). To minimize the possibility of positive
GFP signals transfected from nonintegrating donor plasmid,
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Figure 2. a) Schematic illustration of green fluorescent protein (GFP) transfection in B16 cells treated by Donor-RS1/GFP-plasmid⊂SMNPs. b) Eigh-
teen formulations of Donor-RS1/GFP-plasmid⊂SMNPs were prepared for the GFP-transfection study, followed by fluorescence microscopy analysis.
c) Quantitative analysis of the fluorescent micrographs revealed an optimal formulation (*) for Donor-RS1/GFP-plasmid⊂SMNPs.
a time-dependent study was conducted on B16 cells treated by
both plasmid⊂SMNPs or Donor-RS1/GFP-plasmid⊂SMNPs
alone at 2, 3, 5, 7, 14, and 21 d post treatment. As shown in
Figure S9a in the Supporting Information, the cells treated by
Donor-RS1/GFP-plasmid⊂SMNPs alone showed the highest
GFP-transfection performance at 3 d post treatment, and the
GFP signals gradually decayed and diminished completely by
14 d. The cells treated by both plasmid⊂SMNPs exhibited stable
GFP signals post 21 d treatment. After 21 d, the cells were
subjected to flow cytometry analysis (Figure S9b,c, Supporting
Information) to determine the knockin efficiency (10.7%) and
obtain sorted RS1/GFP-knockin B16 cells. The sorted RS1/GFP-
knockin B16 cells were subjected to 20 rounds of culture
expansion. Over the culture expansion, these cells still presented
stable and consistent GFP signals (Figure 4b; Figure S10,
Supporting Information), supporting the integration of the
RS1/GFP gene. To test the success of CRISPR-Cas9-mediated
knockin of RS1/GFP gene into the Rosa26 site via the HITI path-
way, we extracted the genomic DNA from RS1/GFP-knockin
B16 cells, followed by PCR analysis and Sanger sequencing.
After PCR amplification, the two characteristic DNA fragments,
i.e., the R-arm junction (617 bp) and L-arm junction (748 bp)—
signifying the integration of 3.0-kb RS1/GFP into the Rosa26
site—were detected by electrophoresis (Figure 4c). In parallel,
Sanger sequencing of the genome-donor boundaries in the
R-arm and L-arm junctions confirmed the successful integration
of RS1/GFP gene via the HITI pathway (Figure 4d). Moreover, to
examine whether the RS1/GFP-knockin B16 cells were capable
of functionally expressing RS1 gene, we carried out quantitative
PCR analysis in RS1/GFP-knockin B16 cells, using untreated
B16 cells as controls. We observed a significantly high level
of RS1 expression in RS1/GFP-knockin B16 cells (Figure 4e).
RS1/GFP-knockin B16 cells were subjected to immunofluores-
cence (IF) staining to examine whether the integrated RS1 gene
in RS1/GFP-knockin B16 cells could functionally express RS1
protein. As shown in Figures 4f and Figure S11 (Supporting In-
formation), strong red fluorescence signals (marking IF-stained
RS1 protein) were observed in RS1/GFP-knockin B16 cells.
Collectively, our in vitro study suggested that the combined
use of Cas9/sgRNA-plasmid⊂SMNPs and Donor-RS1/GFP-
plasmid⊂SMNPs can successfully achieve CRISPR/Cas9-
mediated knockin of a single-copy 3.0-kb RS1/GFP gene into the
mouse Rosa26 site. These results represent the first demonstra-
tion of CRISPR/Cas9-mediated knockin of a long/intact gene
using nonviral vector-based gene-delivery approach.
Following the successful demonstration of in vitro
CRISPR/Cas9-mediated knockin, we were keen to explore
the feasibility of performing CRISPR/Cas9 knockin of RS1/GFP
gene in vivo. A 5 µL phosphate-buffered saline (PBS) solution
containing sterilized Cas9/sgRNA-plasmid⊂SMNPs and Donor-
RS1/GFP-plasmid⊂SMNPs (each 50-ng plasmid) was injected
intravitreally into the eye of a BALB/c-strain mouse (n = 6)
under brief isoflurane anesthesia. Figure 5a shows the timeline
of our in vivo study over a period of 30 d. At days 3, 10, and
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Figure 3. a) Schematic illustrations of optimal Cas9/sgRNA-plasmid⊂SMNPs, Donor-RS1/GFP-plasmid⊂SMNPs, and the coencapsulated Cas9/sgRNA-
plasmid+Donor-RS1/GFP-plasmid⊂SMNPs. b) Scanning electron microscopy (SEM) and c) transmission electron microscopy (TEM) images summa-
rize the size distributions of these three SMNPs. The size distributions of SMNPs in the TEM and SEM images were measured via Nano measure 1.2
software. More than 200 SMNPs were counted in each sample.
30 postinjection, a fundus camera and OCT were used to mea-
sure the knockin GFP signals on retinal surfaces (left andmiddle
panels in Figure 5b and Figure S12a in the Supporting Infor-
mation) and to monitor the anatomical structures of the retinas
(right panels in Figure 5b and Figure S12a in the Supporting
Information), respectively. Bright-field fundus and OCT imaging
suggested that the mice retinas retained anatomical integrity
over the course of the study. The GFP signals associated with
CRISPR/Cas9-mediated knockin of RS1/GFP gene emerged
at day 18 and persisted until day 30. At day 30, the mice were
euthanized by cervical dislocation under deep anesthesia, and
the treated eyes were excised for pathological and molecular
analyses. After dissecting retinas from the treated eyes, the
GFP-positive areas were subjected to standard pathology H&E
staining and IHC staining for GFP (Figure 5c; Figure S12b, Sup-
porting Information). Two pathologists reviewed all the slides
Adv. Sci. 2020, 7, 1903432 1903432 (7 of 11) © 2020 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.advancedsciencenews.com www.advancedscience.com
Figure 4. a) A timeline depicting CRISPR/Cas9-mediated knockin of RS1/GFP gene in growth-synchronized B16 cells using both Cas9/sgRNA-
plasmid⊂SMNPs and Donor-RS1/GFP-plasmid⊂SMNPs. b) Bright-field and fluorescence images of sorted RS1/GFP-knockin B16 cells taken after
20 rounds of culture expansion. c) Two characteristic DNA fragments, i.e., the R-arm junction (617 bp) and L-arm junction (748 bp)—signifying the
integration of RS1/GFP into the Rosa26 site—were detected by an electrophoretogram. d) Sanger sequencing was carried to test that the correct DNA
sequences of the genome-donor boundaries in the R-arm and L-arm junctions. e) RS1 gene expression levels observed by quantitative PCR. f) Repre-
sentative immunofluorescence images of RS1/GFP-knockin B16 cells.
independently, concluding that: (1) no histological abnormalities
were observed, and (2) GFP positivity was identified in the
ganglion cell layers of the retinas. In parallel, genomic DNA was
extracted from the GFP-positive retina tissues to confirm that
the RS1/GFP gene was correctly integrated into the Rosa26 site.
After PCR amplification, the two characteristic fragments, i.e.,
the R-arm junction (617 bp) and L-arm junction (748 bp) were
observed on an electrophoretogram (Figure 5d). Sanger sequenc-
ing of the genome-donor boundaries in the R-arm and L-arm
junctions indicated the successful integration of RS1/GFP gene.
(Figure 5e). Collectively, these in vivo experimental data support
that the SMNP vectors can be utilized to deliver CRISPR/Cas9
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Figure 5. a) A timeline and graphic illustration depicting CRISPR/Cas9-mediated knockin of the RS1/GFP gene in mouse retina via intravitreal injection
of both Cas9/sgRNA-plasmid⊂SMNPs and Donor-RS1/GFP-plasmid⊂SMNPs. b) A fundus camera and optical coherence tomography (OCT) were
employed to detect the GFP signals on retinal surfaces and monitor the anatomical structures of the retinas, respectively. c) H&E staining and IHC
staining for GFP of the GFP-positive retina tissues. d) Two characteristic DNA fragments, i.e., the R-arm junction (617 bp) and L-arm junction (748 bp)
on an electrophoretogram and e) Sanger sequencing of the genome-donor boundaries in the R-arm and L-arm junctions confirmed the successful
integration of 3.0-kb RS1/GFP gene into the Rosa26 site in vivo.
gene editing system and dDNA using theHITI strategy, enabling
CRISPR/Cas9-mediated knockin of intact RS1 gene in retina as
a potential nonviral therapeutic solution for treating XLRS.
In summary, we introduced an in vivo CRISPR/Cas9-mediated
knockin approach using two SMNP vectors, i.e., Cas9/sgRNA-
plasmid⊂SMNPs and Donor-RS1/GFP-plasmid⊂SMNPs, which
were identified by performing small-scale combinatorial screen-
ings of the different SMNP formulations prepared by a self-
assembly synthetic strategy. By intravitreally injecting the two
SMNP vectors in BALB/c-strain mice, we successfully demon-
strated CRISPR/Cas9-mediated knockin of 3.0-kb RS1/GFP gene
into the Rosa26 site in mice retinas. This proof-of-concept study
highlights the potential of the combined use of the SMNP vectors
with the HITI strategy to achieve in vivo CRISPR/Cas9-mediated
Adv. Sci. 2020, 7, 1903432 1903432 (9 of 11) © 2020 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
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knockin of a therapeutic gene. Since nearly 200 mutation sites in
the RS1 gene have been identified and associated with XLRS, it
is not feasible to develop CRISPR/Cas9-mediated editing accord-
ing to individual patients’ mutations. Performing CRISPR/Cas9-
mediated knockin of the RS1 gene in the retinas of XLRS pa-
tients via either intravitreal or subretinal injection of the SMNPs
would offer a revolutionary curative therapeutic solution. The
same strategy should apply for treating other genetic diseases in
which specificmutations only function in local organs (e.g., cystic
fibrosis).
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